Recent Progress in Clinical Application of Ranibizumab / 中国药师

ABSTRACT

Ranibizumab is a recombinant rat monoclonal antibody fragment of the second generation humanized VEGF. Ranibi-zumab can bind all of active VEGF-A to inhibit the bond between VEGF-A and VEGFR1 or VEGFR2. As the results, the vascular en-dothelial proliferation and vascular permeability can be reduced, and the new vessels angiogenesis can be prevented. The article sys-tematically searched and summarized the relative literatures to offer high-quality evidences for the recent clinical application of ranibi-zumab in ophthalmology.